Y-mAbs Therapeutics, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Michael Rossi
- Full Time Employees
- 104
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 230 Park Avenue Princeton NY United States of America 10169
- IPO Date
- Sep 21, 2018
- CIK
- 0001722964
- Website
- ymabs.com
- Similar Companies
- Business
- Y-mAbs Therapeutics, Inc. is a commercial-stage biopharmaceutical company specializing in the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer. Its main products include DANYELZA (naxitamab-gqgk), a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) designed for treating pediatric patients one year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also advancing several clinical-stage candidates including GD2-SADA in Phase I trials for GD2 positive solid tumors, Omburtamab for central nervous system/leptomeningeal metastases from neuroblastoma, and CD38-SADA along with a GD2-GD3 Vaccine under development. Y-mAbs leverages proprietary self-assembly disassembly pretargeted radioimmunotherapy (SADA PRIT) technology to deliver targeted radioactive payloads to tumors. The company operates primarily in the United States but also has activities in Western Europe, Eastern Asia, Latin America, and Western Asia. Founded in 2015, Y-mAbs Therapeutics is headquartered in Princeton, New Jersey. A major recent development for Y-mAbs Therapeutics is its acquisition by SERB Pharmaceuticals, completed in September 2025. This transaction, valued at approximately $412 million, involved an all-cash offer with Y-mAbs becoming a wholly owned subsidiary of SERB. The acquisition significantly strengthens SERB's rare oncology portfolio through the addition of Y-mAbs’ FDA-approved DANYELZA product and expands collaborative opportunities within the U.S. oncology community. Prior to the acquisition, Y-mAbs had entered strategic partnerships such as exclusive distribution agreements to expand DANYELZA’s access in Latin America and a collaboration with WEP Clinical to provide DANYELZA in Europe via Named Patient Programs. Additionally, Y-mAbs has been advancing its radiopharmaceutical pipeline, including Phase I clinical trials of GD2-SADA and CD38-SADA, alongside nonclinical optimization studies to enhance its targeted therapies. Y-mAbs Therapeutics operates in the biotechnology sector with a focus on oncology, particularly pediatric cancers. Its products and pipeline candidates target rare and aggressive cancers through antibody-based and radioimmunotherapy treatments. The company’s business model integrates cutting-edge scientific platforms for antibody engineering and targeted radioactive delivery, working through licensing agreements with prestigious institutions such as Memorial Sloan Kettering Cancer Center and the Massachusetts Institute of Technology. The company’s leadership continues to emphasize expanding the commercial reach and clinical development of innovative cancer therapies globally under the strategic umbrella of SERB Pharmaceuticals. This detailed profile reflects Y-mAbs Therapeutics’ product offerings, geographic footprint, recent acquisition, and ongoing developmental progress, anchored in its founding year of 2015 and Princeton, New Jersey headquarters. The acquisition by SERB Pharmaceuticals and established international partnerships mark significant strategic expansions for the company’s future growth and commercial success in rare oncology treatment.
Y-mAbs Therapeutics, Inc. (YMAB) Now Trades Above Golden Cross: Time to Buy?
Y-MABS THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Y-mAbs Therapeutics, Inc. - YMAB
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Tops Revenue Estimates
Shareholder Alert: The Ademi Firm Investigates Whether Y-mAbs Therapeutics Inc. is Obtaining a Fair Price for its Public Shareholders
Y-mAbs (YMAB) Q2 Revenue Falls 14%
Y-mAbs Reports Second Quarter 2025 Financial Results and Recent Corporate Developments
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB)
Y-MABS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Y-mAbs Therapeutics, Inc. - YMAB
Y-mAbs to Announce Second Quarter 2025 Financial and Operating Results on August 8, 2025
YmAbs Therapeutics (YMAB) Surges 103.3%: Is This an Indication of Further Gains?
Y-mAbs Therapeutics upgraded to Equal Weight from Underweight at Morgan Stanley
Y-mAbs Therapeutics downgraded to Hold from Buy at Canaccord
Y-mAbs Therapeutics downgraded to Perform from Outperform at Oppenheimer
Y-mAbs Therapeutics downgraded to Hold from Buy at Brookline
Y-mAbs Therapeutics downgraded to Hold from Buy at Truist
Shareholder Alert: The Ademi Firm investigates whether Y-mAbs Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders
YMAB Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Y-mAbs Therapeutics, Inc. Is Fair to Shareholders
SERB Pharmaceuticals Agrees to Acquire Y-mAbs Therapeutics
YmAbs Therapeutics (YMAB) Upgraded to Buy: Here's What You Should Know
Y-mAbs Hosts Virtual Radiopharmaceutical R&D Update Highlighting Clinical Progress and Expanded Pipeline